‘A Game Changer’: New Combination Immunotherapy for Advanced Melanoma Offers More Options For Patients
Source: Survivor Net, April 2022
A New Melanoma Treatment
- The U.S. Food and Drug Administration has approved a new combination immunotherapy option for melanoma that cannot be treated with surgery (unresectable) or melanoma that has spread (metastatic).
- Opdualag is a combination of two immunotherapies — nivolumab and relatlimab. In a clinical trial, Opdualag more than doubled the median time it took for patients’ disease to progress.
- Common side effects included itching (pruritus), fatigue, and rash.
A newly-approved immunotherapy drug combination for the deadliest form of skin cancer will change the way patients are treated for the disease, experts tell SurvivorNet.
The U.S. Food and Drug Administration’s approval of Opdualag (nivolumab + relatlimab) for melanoma that cannot be treated with surgery (unresectable) or melanoma that has spread (metastatic), offers a new, potentially more powerful solution for treating this type of skin cancer, which claims about 7,700 lives per year.READ THE ORIGINAL FULL ARTICLE